The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1609
ISSUE1609
October 19, 2020
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
October 19, 2020 (Issue: 1609)
The FDA has approved a sublingual fi lm formulation
of the nonergot dopamine agonist apomorphine
(Kynmobi – Sunovion) for acute, intermittent treatment
of "off" episodes in patients with Parkinson's disease
(PD). A subcutaneous formulation of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.